Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2025
0mins
Source: Yahoo Finance
Lecanemab Presentation at AAIC: Eisai will present new findings on lecanemab, including four-year efficacy and safety data, as well as a subcutaneous formulation for maintenance dosing, at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025.
Collaboration and Commercialization: BioArctic and Eisai have a long-term partnership for developing lecanemab, which is approved in multiple countries for early Alzheimer's disease treatment, with BioArctic set to commercialize it in the Nordic region.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
